<DOC>
	<DOCNO>NCT02857868</DOCNO>
	<brief_summary>The main purpose study evaluate effect vary degree impair hepatic function ( Child-Pugh classification ) pharmacokinetics ( PK ) ABL001 single oral dose .</brief_summary>
	<brief_title>A Trial Evaluate Pharmacokinetics ABL001 Healthy Hepatic Impaired Subjects</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Key Inclusion criterion : Body mass index 1836 kg/m2 , body weight 50 kg 120 kg Vital sign ( least 3 minute rest supine position ) within follow range ( inclusive ) : Oral body temperature 35.0 °C 37.5 °C ( 95.099.5°F ) Systolic BP ≥90 mmHg ≤140 mmHg Diastolic BP ≥60 mmHg ≤90 mmHg healthy subject 50100 mmHg subject impair hepatic function ( group 24 ) Pulse Rate : ≥50 ≤90 bpm healthy subject ( group 1 ) ≥50 ≤100 bpm subject impair hepatic function ( group 24 ) Healthy subject clinically significant abnormality determine past medical history , physical examination , vital sign , ECG , clinical laboratory test Subjects ChildPugh Clinical Assessment Score calculate per ChildPugh classification Key Presence clinically significant ECG abnormality family history presence prolong QTinterval syndrome History cardiac disease Sexually active male must use condom intercourse take drug 7 day stop Any surgical medical condition might significantly alter absorption , distribution , metabolism excretion drug Administration strong moderate CYP3A4 inhibitor inducer ( include St John 's wort ) within 14 day prior dose Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hepatic Impairment</keyword>
	<keyword>ABL001</keyword>
	<keyword>Child-Pugh</keyword>
	<keyword>healthy subject normal hepatic function</keyword>
</DOC>